William Blair Upgrades Gen-Probe (GPRO) to Outperform
More News related to GPRO
- Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today
- Neogen Acquires Gen-Probe's BioKits Food Safety Business
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA
- Trading Review for Cerus Corp. Issued by Beacon Equity
More News related to Upgrades
- Knight (KNX), USA Truck (USAK), Werner (WERN) Higher Amid Avondale Upgrades
- William Blair Upgrades Manpower (MAN) Amid Strong Jobs Report
- Pritchard Capital Upgrades Geokinetics (GOK) to Buy
- Argus Upgrades ADC Telecommunications (ADCT) to Buy
- Oppenheimer Upgrades Akamai Tech (AKAM) to Outperform
William Blair upgrades Gen-Probe (Nasdaq: GPRO) from Market Perform to Outperform.
To see more analyst ratings on GPRO Click Here.
Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally.
Related Categories
UpgradesStocks Mentioned
+0.99Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
